Claritas Pharmaceuticals Inc V.CLAS.H

NEWS: Claritas Announces Settlement of Debt Transaction

[Amazigh]

Claritas Announces Settlement of Debt Transaction SAN FRANCISCO, CA and TORONTO, ON -- (April 7, 2021) Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into an agreement to pay amounts owing to a service provider for past services in common shares of the Company (Common Shares). The transaction is subject to approval by the TSX Venture Exchange (the TSXV). The debt owing is in the amount of USD $35,000 (or CAD $43,825.25 based on the daily average exchange rate for April 7, 2021 published by the Bank of Canada). This debt (the Debt) is owed to Cova Capital Partners, LLC (Cova), and is the cash commission that the Company agreed to pay to Cova for broker services provided by Cova relating to the Companys previously announced private placement of common shares and common share purchase warrants on September 16, 2019. The Company will issue to Cova 973,894 common shares, based on the deemed share price of $0.045. The Company will issue these Common Shares upon approval of the TSXV.